Nykode Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Nykode Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-54.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-54.9%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Aug 05

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 02

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Jan 22

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Aug 20

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Apr 06

Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?

Jan 25

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NYKD şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NYKD şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Nykode Therapeutics Piyasaya Karşı Temettü Getirisi

NYKD temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NYKD)	n/a
Pazarın Alt %25'i (NO)	3.4%
Pazarın En İyi %25'i (NO)	7.7%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (NYKD) (3 yıla kadar)	0%

Önemli Temettü: NYKD şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NYKD şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NYKD şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NYKD herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Nykode Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Price target decreased by 21% to kr22.00

New minor risk - Market cap size

Nykode Therapeutics ASA Announces Updates on its Inverse Vaccine Platform at Pegs Europe

Consensus revenue estimates decrease by 19%

Price target decreased by 20% to kr29.13

Consensus revenue estimates decrease by 54%, EPS upgraded

Chairman of the Board recently bought kr283k worth of stock

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

New minor risk - Share price stability

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting

Consensus revenue estimates decrease by 35%, EPS upgraded

Consensus revenue estimates increase by 37%, EPS downgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Director recently bought kr310k worth of stock

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases

Price target decreased by 36% to kr43.00

Consensus EPS estimates upgraded to US$0.18 loss

Chief Executive Officer recently bought kr100k worth of stock

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Nykode Therapeutics AS to Report Q4, 2024 Results on Feb 26, 2025

Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer

Third quarter 2023 earnings released: US$0.03 loss per share (vs US$0.05 loss in 3Q 2022)

New minor risk - Shareholder dilution

Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer

Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research

Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the Next Trial in Advanced Cervical Cancer

Nykode Therapeutics AS Announces Management Changes

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.033 loss in FY 2021)

Director exercised options and sold kr7.4m worth of stock

Nykode Therapeutics AS to Report Q3, 2023 Results on Nov 15, 2023

Nykode Expands Clinical Development Plan for Its Lead Cancer Vaccine Vb10.16 in Hpv16-Positive Cancers

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.03 loss in 3Q 2021)

No independent directors

Nykode Therapeutics Presents Additional Efficacy Analysis in Phase 2 Study of VB10.16 in Combination with Atezolizumab in Advanced Cervical Cancer

Nykode Therapeutics ASA Announces Presentation of Positive Immunogenicity Results from Phase 1/2A Study of VB10.NEO

Nykode Therapeutics ASA Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Second quarter 2022 earnings released: US$0.03 loss per share (vs US$0.02 loss in 2Q 2021)

Nykode Therapeutics Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial

Nykode Therapeutics AS Appoints Klaus Edvardsen as Chief Development Officer, Effective from July 1, 2022

Chairman of the Board recently bought kr321k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nykode Therapeutics AS Appoints Elaine Sullivan and Anne Whitaker to the Board of Directors

Nykode Therapeutics AS Announces Positive Interim Results from Its Phase 2 Trial with VB10.16 in Combination with Immune Checkpoint Inhibitor Atezolizumab in Advanced Cervical Cancer

No independent directors

Nykode Therapeutics as Announces Presentation of Preclinical Data from Its Second Generation Vaccibody Vaccine Technology At 2022 American Association for Cancer Research (AACR) Annual Meeting

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Nykode Therapeutics Announces Completion of Patient Enrollment in Its Phase 2 Trial of Vb10.16 in Combination with Atezolizumab for the Treatment of Advanced Cervical Cancer

Investor sentiment deteriorated over the past week

Nykode Therapeutics AS Announces First Subject Dosed with Its T Cell Focused Next-Generation SARS-CoV-2 Vaccine Candidate

Director recently bought kr26m worth of stock

Nykode Therapeutics Announces Phase 1/2 Clinical Trial With Next Generation DNA-Based COVID-19 Vaccine Candidates

Key Executive recently sold kr21m worth of stock

Vaccibody AS announced that it expects to receive NOK 178.305538 million in funding from Regeneron Pharmaceuticals, Inc.

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.03 loss per share (vs US$0.017 loss in 3Q 2020)

Director recently sold kr112m worth of stock

Second quarter 2021 earnings released: US$0.02 loss per share (vs US$0.02 loss in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$2.00 loss per share (vs US$0.011 loss in 1Q 2020)

Director has left the company

Chief Financial Officer has left the company